Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Transdermal scopolamine in drooling.

E Brodtkorb1, M M Wyzocka-Bakowska, P E Lillevold

  • 1Department of Neurology, Trondheim University Hospital, Norway.

Journal of Mental Deficiency Research
|June 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk of preterm birth in relation to history of preterm birth: a population-based registry study of 213 335 women in Norway.

BJOG : an international journal of obstetrics and gynaecology·2021
Same author

Development of clinical competence - a longitudinal survey of nurse practitioner students.

BMC nursing·2021
Same author

Clinical impact of chronic substance abuse in a Norwegian ICU-population.

Acta anaesthesiologica Scandinavica·2020
Same author

Multidisciplinary educational programme for caregivers of children with atopic dermatitis- in South East Norway - an observational study.

BMC dermatology·2020
Same author

Development and validation of a curriculum for laparoscopic supracervical hysterectomy.

Facts, views & vision in ObGyn·2020
Same author

Development and validation of a general and easy assessable scoring system for laparoscopic skills using a virtual reality simulator.

European journal of obstetrics & gynecology and reproductive biology: X·2019
Same journal

Increased activity of pyridoxal kinase in tongue in Down's syndrome.

Journal of mental deficiency research·1991
Same journal

Effect of thyroid stimulating hormone on adaptive behaviour in Down's syndrome.

Journal of mental deficiency research·1991
Same journal

Behavioural observations in children with Down's syndrome.

Journal of mental deficiency research·1991
Same journal

Balanced chromosomal translocations and mental illness.

Journal of mental deficiency research·1991
Same journal

Mental retardation and WAIS-R difference scores.

Journal of mental deficiency research·1991
Same journal

The psychometric properties of the Behaviour Assessment Record (the BAR schedule).

Journal of mental deficiency research·1991
See all related articles

Transdermal scopolamine patches effectively reduced drooling in patients with intellectual disabilities. This treatment offers a stable dose over three days with minimal side effects, providing a potential symptomatic option.

Area of Science:

  • Pharmacology
  • Neurology
  • Gastroenterology

Background:

  • Oral anticholinergic drugs have limited efficacy for treating drooling.
  • Transdermal scopolamine offers a sustained release formulation for consistent dosing.

Purpose of the Study:

  • To evaluate the efficacy and safety of transdermal scopolamine in reducing drooling.
  • To compare transdermal scopolamine with placebo in a double-blind, cross-over trial.

Main Methods:

  • An open trial in six healthy volunteers assessed salivation reduction.
  • A double-blind, placebo-controlled cross-over trial involved 18 patients with drooling.
  • Visual analogue scales were used to assess therapeutic effects.

Main Results:

Related Experiment Videos

  • Transdermal scopolamine demonstrated a distinct reduction in basal salivation in healthy volunteers.
  • In patients, transdermal scopolamine significantly reduced drooling between 24 and 72 hours post-application.
  • Adverse effects were minimal and mild, with drowsiness and potential dental issues noted.

Conclusions:

  • Transdermal scopolamine is a viable option for symptomatic treatment of drooling, especially when other methods are insufficient.
  • It provides a stable serum concentration for up to 3 days.
  • Management of drooling should prioritize addressing underlying causes and contributing factors.